Zhanbo W. Wang

No. 28 Fuxing Road
Haidian, 100853, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B

Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: February 02, 2026

Silk fibroin scaffolds loaded with growth factors can reverse liver fibrosis.

Silk fibroin scaffolds loaded with growth factors can reverse liver fibrosis.

Journal: Biomaterials science

Published: January 23, 2026

Three-dimensional-printed silk fibroin scaffolds loaded with adipose-derived stem cells prevent post endoscopic submucosal dissection esophageal stricture in a porcine model.

Three-dimensional-printed silk fibroin scaffolds loaded with adipose-derived stem cells prevent post endoscopic submucosal dissection esophageal stricture in a porcine model.

Journal: Regenerative biomaterials

Published: November 18, 2025

Tissue-engineered liver using 3D-printed silk fibroin scaffolds loaded with stem cells for the treatment of acute liver injury.

Tissue-engineered liver using 3D-printed silk fibroin scaffolds loaded with stem cells for the treatment of acute liver injury.

Journal: Regenerative biomaterials

Published: June 25, 2025

Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.

Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.

Journal: Signal transduction and targeted therapy

Published: June 25, 2025

Adipose derived mesenchymal stem cell-seeded regenerated silk fibroin scaffolds reverse liver fibrosis in mice.

Adipose derived mesenchymal stem cell-seeded regenerated silk fibroin scaffolds reverse liver fibrosis in mice.

Journal: Journal of materials chemistry. B

Published: March 10, 2025

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Journal: Bioscience trends

Published: December 25, 2024

The Expression and Clinicopathological Significance of BRAF V600E and Mucin 6 in Intrahepatic Cholangiocarcinoma: A Retrospective Study.

The Expression and Clinicopathological Significance of BRAF V600E and Mucin 6 in Intrahepatic Cholangiocarcinoma: A Retrospective Study.

Journal: International journal of surgical pathology

Published: September 09, 2024

Value of EUS-guided through-the-needle biopsy in the diagnosis of pancreatic cystic neoplasms: An 8-year experience.

Value of EUS-guided through-the-needle biopsy in the diagnosis of pancreatic cystic neoplasms: An 8-year experience.

Journal: Endoscopic ultrasound

Published: March 27, 2024

Multiparametric US for Identifying Metabolic Dysfunction-associated Steatohepatitis: A Prospective Multicenter Study.

Multiparametric US for Identifying Metabolic Dysfunction-associated Steatohepatitis: A Prospective Multicenter Study.

Journal: Radiology

Published: March 19, 2024

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

Journal: Journal for immunotherapy of cancer

Published: August 08, 2023

Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

Journal: Frontiers in immunology

Published: May 09, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026